Regenerative medicine最新文献

Cardiac bioprinting holds great promise for creating patient-specific grafts and physiologically relevant drug-testing platforms, yet several critical challenges remain. This review identifies key barriers in current cardiac bioprinting approaches, including limitations in bioprinting precision, bioink development, vascularization, functional maturation, and scalable cell sourcing and processing. Recent advances, such as multimodal printing, hybrid bioinks, and perfusable constructs, are discussed with a focus on their application to drug discovery and graft fabrication. We emphasize that targeted maturation may suffice for drug screening, while graft applications demand greater complexity, scale, and immune compatibility. Addressing these challenges through integrated, multidisciplinary strategies will be essential to advance cardiac bioprinting toward clinical and preclinical impact.

Avascular necrosis (AVN), also referred to as osteonecrosis (ON), is a major clinical challenge in orthopedic practice. Current treatment strategies include surgical options such as core decompression, as well as non-surgical approaches including statin therapy, weight reduction, and physiotherapy. Regenerative therapies - such as platelet-rich plasma injections, autologous bone marrow cell concentrates, and mesenchymal stem/stromal cells (MSCs), among others have shown some success. Although induced pluripotent stem cells (iPSCs) represent a promising source for cell therapy, their clinical application is restricted due to the risk of teratoma formation. In this context, the therapeutic potential of extracellular vesicles (EVs) secreted by stem cells has emerged as a relatively new area of investigation. This review summarizes findings from preclinical studies in animal models that have explored the use of MSC- and iPSC-derived EVs in the regenerative treatment of AVN/ON. Compared with MSC-EVs, the therapeutic use of iPSC-EVs has progressed more slowly, partly due to the high cost of expanding iPSCs to obtain a sufficient quantity of their EVs. Therefore, instead of using iPSC-derived EVs, the use of a cocktail of EVs secreted by iPSC-derived cellular derivatives may represent a safer, more cost-effective, and potentially more efficacious strategy for treating AVN.

Latest developments in the field of Advanced Therapy Medicinal Products and regenerative medicine compiled from publicly available information and press releases from non-academic institutions in July 2025.

Latest developments in the field of stem cell research and regenerative medicine compiled from publicly available information and press releases from non-academic institutions in April 2025.

Dry eye disease (DED) is a multifactorial condition that significantly impairs patients' quality of life, particularly in its severe forms, which are often unresponsive to conventional therapies. In this retrospective study, we evaluated the long-term efficacy and safety of subconjunctival platelet-rich plasma (PRP) injections in six Hispanic women with refractory DED. A total of eleven eyes were treated with a standardized protocol consisting of five PRP injections - three administered monthly, followed by two spaced two months apart - and followed for a period of 12 months. Clinical assessments included both subjective and objective measures, such as the Ocular Surface Disease Index (OSDI), Schirmer test, tear breakup time (BUT), and ocular surface staining with fluorescein and lissamine green. Significant and sustained improvements were observed across all parameters throughout the follow-up period, and no serious adverse events were reported. Notably, this is the first study to demonstrate that subconjunctival PRP injections may provide long-term symptomatic relief in patients with refractory DED. These findings suggest that this novel, well-tolerated, and accessible therapeutic approach may represent a promising alternative for individuals who do not respond to conventional treatments and warrant further investigation in larger populations.

Regenerative endodontics has emerged as a promising and recognized approach for treating necrotic young permanent teeth. Based on advanced tissue engineering strategies, regenerative therapies, such as cell homing and cell-based transplantation, have been extensively investigated to achieve functional regeneration of the injured pulp-dentin complex. Injectable, thermo-responsive, and tailor-made 3D-printed scaffolds that carry antimicrobial, anti-inflammatory, and other signaling cues provide a powerful means of delivering drugs precisely within the narrow, branching anatomy of the root canal. By enhancing antimicrobial decontamination, an essential step in the regenerative process, these biomaterials establish a permissive microenvironment that promotes cellular migration, adhesion, and subsequent differentiation. Therefore, the current narrative review emphasizes emerging strategies and their optimization to enhance regenerative outcomes in immature teeth affected by pulp necrosis and apical periodontitis.

Adeno-associated virus (AAV) vectors have transformed the landscape of in vivo gene therapy, with retinal diseases emerging as a major area of progress. The eye offers unique advantages as a therapeutic target: it is accessible, compartmentalized, and relatively immune-privileged, allowing localized delivery with reduced systemic effects. The landmark 2017 approval of the first AAV-based gene therapy for an inherited retinal disorder sparked a surge of clinical trials using AAV vectors - underscoring their potential for treating genetic eye diseases. However, challenges remain, including AAV's limited capacity for large genes, suboptimal precision in cell-type-specific targeting, and inefficient transduction of certain retinal cells via minimally invasive routes. In response, researchers are engineering next-generation AAV capsids, optimizing gene expression cassettes, developing novel delivery strategies, and advancing tissue and organoid-based screening platforms. This article highlights these efforts as essential to overcoming current barriers in retinal AAV gene therapy.

Bone regeneration represents a key objective in bone tissue engineering and involves a series of coordinated biological processes, including immunomodulation, neuroregulation, angiogenesis, and osteogenesis. Recent studies have underscored the therapeutic potential of extracellular vesicles (EVs) in promoting osteogenesis and facilitating the repair of bone defects, supporting their application as a promising cell-free strategy in regenerative medicine. Migrasomes, vesicle-like organelles anchored to retraction fibers and first identified in 2015, have emerged as key mediators in intercellular communication, lateral transfer of mRNA and proteins, and mitochondrial homeostasis. Through cell-free treatment, these functions support the activity and regenerative ability of stem cells during bone repair. This review provides an updated overview of migrasome-related research, emphasizing their roles in molecular delivery and regulation during bone regeneration. Moreover, the potential of migrasomes as innovative tools for bone tissue engineering is discussed, along with prospective strategies to enhance their utility through advances in understanding their biogenesis and cargo sorting. Despite their known biological functions, the therapeutic applications of migrasomes in bone regeneration remain largely unexplored, highlighting the need for further investigation in this emerging field.

Latest developments in the field of stem cell research and regenerative medicine compiled from publicly available information and press releases from non-academic institutions in March 2025.